Genomic Valley Biotech Fair Value
Genomic Valley Biotech (GVBL) average fair value is ₹20.01 across 3 valuation models — P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, vs a current market price of ₹24.25 (-17.5%), fair value range ₹11.96–₹34.73. For live price and a broader fundamental view, visit GVBL share price.
Fair Value Analysis Export
GVBL Fair Value vs Current Price — Valuation Summary
GVBL average fair value, fair value range, price gap and valuation status across 3 models: P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation. Also explore GVBL price movement history to track price trends across different timeframes.
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
GVBL Fair Value Analysis — Data Sources & Coverage
Genomic Valley Biotech financial data sources, valuation methods applied and sector benchmarks used. See GVBL price book multiple to compare market price against book value per share.
Available Data Sources: Financial statements, balance sheet data , sector comparisons.
GVBL vs Healthcare Sector Peers — P/E, P/B & Market Cap
Genomic Valley Biotech P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Jeena Sikho Lifecare | JSLL | 40.38 | 23.07 | ₹7,944 |
| Accretion Pharmaceuticals | ACCPL | 17.91 | 2.7 | ₹120 |
| Par Drugs & Chemical | PAR | 8.2 | 0.96 | ₹103 |
| Murae Organisor | MURAE | 2.86 | 0.2 | ₹41 |
| KRM Ayurveda | KRMAYURVED | - | 4.07 | ₹508 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.